EGFR and non-small cell lung carcinoma: Studies have shown that (the) combination (of) chemotherapy with EGFR tyrosine kinase inhibitors could be given to patients as first-line treatment.5,6 It is, therefore, important to assess the EGFR mutation in the patients with NSCLC.